Clozapine or Haloperidol in rats prenatally exposed to methylazoxymethanol, a compound inducing entorhinal-hippocampal deficits, alter brain and blood neurotrophins' concentrations

Annali dell'Istituto Superiore di Sanita

Volumn 44, Issue 2, 2008, Pages 167-177

  Fiore, Marco ^a   Di Fausto, Veronica ^a   Iannitelli, Angela ^b   Aloe, Luigi ^a  

^a CNR   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

BDNF; Clozapine; Haloperidol; MAM; NGF; Schizophrenia

Indexed keywords

ALKYLATING AGENT; CLOZAPINE; DRUG DERIVATIVE; HALOPERIDOL; METHYLAZOXYMETHANOL; METHYLAZOXYMETHANOL ACETATE; NERVE GROWTH FACTOR; NEUROLEPTIC AGENT;

ANIMAL; ARTICLE; BLOOD; BODY WEIGHT; BRAIN LEVEL; CONGENITAL MALFORMATION; DRUG EFFECT; ENTORHINAL CORTEX; FEMALE; GRANULOCYTE; HIPPOCAMPUS; METABOLISM; PATHOLOGY; PREGNANCY; PRENATAL EXPOSURE; RAT; SPRAGUE DAWLEY RAT;

ALKYLATING AGENTS; ANIMALS; ANTIPSYCHOTIC AGENTS; BODY WEIGHT; BRAIN CHEMISTRY; CLOZAPINE; ENTORHINAL CORTEX; FEMALE; GRANULOCYTES; HALOPERIDOL; HIPPOCAMPUS; METHYLAZOXYMETHANOL ACETATE; NERVE GROWTH FACTORS; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 49049118476     PISSN: 00212571     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Rapoport JL, Addington AM, Frangou S, Psych MR. The neurodevelopmental model of schizophrenia: update 2005. Mol Psychiatry 2005;10:434-49.
2. Arnold S.E. Cellular and molecular neuropathology of the parahippocampal region in schizophrenia. Ann New York Acad Sci 2000;911:275-92.
3. Gold JM, Weinberger DR. Cognitive deficits and the neurobiology of schizophrenia. Curr Opin Neurobiol 1995;5:225-30.
4. Kalus P, Slotboom J, Gallinat J, Federspiel A, Gralla J, Remonda L, Strik WK, Schroth G, Kiefer C. New evidence for involvement of the entorhinal region in schizophrenia: a combined MRI volumetric and DTI study. Neuroimage 2005;24:1122-9.
5. Decker MJ, Rye DB. Neonatal intermittent hypoxia impairs dopamine signaling and executive functioning. Sleep Breath 2002;6:205.
6. Hulshoff Pol HE, Hoek HW, Susser E, Brown AS, Dingemans A, Schnack HG, van Haren NE, Pereira Ramos LM, Gispen-de Wied CC, Kahn RS. Prenatal exposure to famine and brain morphology in schizophrenia. Am J Psychiatry 2000;157:1170-2.
7. Sperner-Unterweger B. Immunological aetiology of major psichiatric disorders: evidence and therapeutic implications. Drugs 2005;65:1493-520.
8. Talamini LM, Koch T, Ter Horst GJ, Korf J. Methylazoxymethanol acetate-induced abnormalities in the entorhinal cortex of the rat; parallels with morphological findings in schizophrenia. Brain Res 1998;789:293-306.
9. Talamini LM, Koch T, Luiten PG, Koolhaas JM, Korf J. Interruptions of early cortical development affect limbic association areas and social behaviour in rats; possible relevance for neurodevelopmental disorders. Brain Res 1999; 847:105-20.
10. Fiore M, Korf J, Angelucci F, Talamini L, Aloe L. Prenatal exposure to methylazoxymethanol acetate in the rat alters neurotrophin levels and behavior: considerations for neurodevelopmental diseases. Physiol Behav 2000;71:57-67.
11. Braak H, Braak E. The human entorhinal cortex: normal morphology and lamina specific pathology in various diseases. Neurosci Res 1992;48:825-31.
12. Bayer SA, Altman J. Directions in neurogenetic gradients and patterns of anatomical connections in the telencephalon. Prog Neurobiol 1987;29:57-106.
13. Cattabeni F, Di Luca M. Developmental models of brain dysfunctions induced by targeted cellular ablations with methylazoxymethanol. Physiol Rev 1997;77:199-215.
14. Gloser H. Genetic damage caused by methylazoxymethanol acetate, the aglycone of cycasin. Analysis of sister-chromatid exchange frequency under in vivo conditions and in cell cultures. Oncology 1982;39:101-3.
15. Fiore M, Talamini L, Angelucci F, Koch T, Aloe L, Korf J. Prenatal methylazoxymethanol acetate alters behavior and brain NGF levels in young rats: a possible correlation with the development of schizophrenia-like deficits. Neuropharmacology 1999;38:857-69.
16. Lavin A, Moore HM, Grace AA. Prenatal disruption of neocortical development alters prefrontal cortical neuron responses to dopamine in adult rats. Neuropsychopharmacology 2005;30:1426-35.
17. Moore H, Jentsch JD, Ghajarnia M, Geyer MA, Grace AA. A neurobehavioral systems analysis of adult rats exposed to methylazoxymethanol acetate on E17: implications for the neuropathology of schizophrenia. Biol Psychiatry 2006;60:253-64.
18. Fiore M, Korf J, Antonelli A, Talamini L, Aloe L. Long-lasting effects of prenatal MAM treatment on water maze performance in rats: associations with altered brain development and neurotrophin levels. Neurotoxicol Teratol 2002;24:179-91.
19. Gourevitch R, Rocher C, Le Pen G, Krebs MO, Jay TM. Working memory deficits in adult rats after prenatal disruption of neurogenesis. Behav Pharmacol 2004;15:287-92.
20. Allen SJ, Dawbarn, D. Clinical relevance of the neurotrophins and their receptors. Clin Sci (London) 2006;110:175-91.
21. Chao MV, Rajagopal R, Lee FS. Neurotrophin signalling in health and disease. Clin Sci (London) 2006;110:167-73.
22. Yuen EC, Mobley WC. Therapeutic potential of neurotrophic factors for neurological disorders. Ann Neurol 1996;40:346-54.
23. Durany N, Thome J. Neurotrophic factors and the pathophysiology of schizophrenic psychoses. Eur Psych 2004; 19:326-37.
24. Hellweg R, Von Richthofen S, Anders D, Baethge C, Ropke S, Hartung HD, Gericke CA. The time course of nerve growth factor content in different neuropsychiatric diseases - a unifying hypothesis. J Neur Trans 1998;105:871-903.
25. Jockers-Scherubl MC, Danker-Hopfe H, Mahlberg R, Selig F, Rentzsch J, Schurer F, Lang UE, Hellweg R. Brain-derived neurotrophic factor serum concentrations are increased in drug-naive schizophrenic patients with chronic cannabis abuse and multiple substance abuse. Neurosci Lett 2004;371:79-83.
26. Shoval G, Weizman A. The possible role of neurotrophins in the pathogenesis and therapy of schizophrenia. Eur Neuropsychopharmacol 2005;15:19-329.
27. Thome J, Foley P, Riederer P. Neurotrophic factors and the maldevelopmental hypothesis of schizophrenic psychoses. J Neural Transm 1998;105:85-100.
28. Bersani G, Iannitelli A, Fiore M, Angelucci F, Aloe L. Data and hypotheses on the role of nerve growth factor and other neurotrophins in psychiatric disorders. Med Hypothesis 2000;55:199-207.
29. Bersani G, Iannitelli A, Maselli P, Pancheri P, Aloe L, Angelucci F, Alleva E. Low nerve growth factor plasma levels in schizophrenic patients: a preliminary study. Schizoph Res 1999;37:201-3.
30. Jockers-Scherubl MC, Matthies U, Danker-Hopfe H, Lang UE, Mahlberg R, Hellweg R. Chronic cannabis abuse raises nerve growth factor serum concentrations in drug-naive schizophrenic patients. J Psychopharmacol 2003;17:439-45.
31. Aloe L, Iannitelli A, Alleva E, Angelucci F, Bersani G, Maselli P, Manni, L. Haloperidol administration in humans lowers plasma NGF level: evidence that sedation induces opped effect to arousal. Neuropsychobiology 1997;36:65-8.
32. Jockers-Scherubl MC, Rentzsch J, Danker-Hopfe H, Radzei N, Schurer F, Bahri S, Hellweg R. Adequate antipsychotic treatment normalizes serum nerve growth factor concentrations in schizophrenia with and without cannabis or additional substance abuse. Neurosci Lett 2006;400:262-6.
33. Bersani G, Aloe L, Iannitelli A, Maselli P, Angelucci F, Alleva E, Orsi P, Pancheri P. NGF plasma levels in psychiatric patients treated with ECT: results at IV and VIII ECT Eur Neuropsychopharmacol 1996; 6(Suppl. 3):182.
34. Parikh V, Khan MM, Terry A, Mahadik SP. Differential effects of typical and atypical antipsychotics on nerve growth factor and choline acetyltransferase expression in the cortex and nucleus basalis of rats. J Psych Res 2004;38;521-9.
35. Klyushnik TP, Danilovskaya EV, Vatolkina OE, Turkova IL, Tsutsul'kovskaya MYa, Orlova VA, Kaleda VG. Changes in the serum levels of autoantibody to nerve growth factor in patients with schizophrenia. Neurosci Behav Physiol 1999;29:355-7.
36. Bianchetti A, Ranieri P, Margiotta A, Trabucchi M. Pharmacological treatment of Alzheimer's disease. Aging Clin Exp Res 2006;18:158-62.
37. Weintraub D, Morales KH, Moberg PJ, Bilker WB, Balderston C, Duda JE, Katz IR, Stern MB. Antidepressant studies in Parkinson's disease: a review and meta-analysis. Mov Disord 2005;20:1161-9.
38. Capuano B, Crosby IT, Lloyd EJ. Schizophrenia: genesis, receptorology and current therapeutics. Cur Med Chem 2002;9:521-48.
39. Leucht S, Wahlbeck K, Hamann J, Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003;361:1581-9.
40. Tandon R, Fleischhacker WW. Comparative efficacy of antipsychotics in the treatment of schizophrenia: a critical assessment. Schizoph Res 2005;79:145-55.
41. Palmblad J, Papadaki HA, Eliopoulos G. Acute and chronic neutropenias. What is new? J Int Med 2001;250:476-91.
42. Vorhees CV, Fernandez K, Dumas RM, Haddad RK. Pervasive hyperactivity and long-term learning impairments in rats with induced micrencephaly from prenatal exposure to methylazoxymethanol. Brain Res 1984;317:1-10.
43. Chlan-Fourney J, Ashe R Nylen K, Juorio AV, Li XM. Differential regulation of hippocampal BDNF mRNA by typical and atypical antipsychotic administration. Brain Res 2002;954:11-20.
44. Halim ND, Weickert CS, McClintock BW, Weinberger DR, Lipska BK. Effects of chronic haloperidol and clozapine treatment on neurogenesis in the adult rat hippocampus. Neuropsychopharmacology 2004;29:1063-9.
45. Kapetanovic S, Simpson GM. Review of antipsychotics in children and adolescents. Expert Opin Pharmacother 2006;7:1871-85.
46. Cuello AC. Brain microdissection techniques. (IBRO Handbook Series) Chichester: Wiley; 1983.
47. Aloe L. Adrenalectomy decreases nerve growth factor in young adult rat hippocampus. Proc Natl Acad Sci USA 1989;86:5636-40.
48. Levi-Montalcini R, Aloe L. Silver impregnation method for insect brain, ganglia, dissociated nerve cells in vitro and for the amphibian nervous system. In: A dissection and tissue culture manual of the nervous system. New York: Alan R. Liss, Inc; 1989. p. 280-2.
49. Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psych 1987;44:660-9.
50. Weinberger DR. Cell biology of the hippocampal formation in schizophrenia. Biol Psych 1999;45:395-402.
51. Di Fausto V, Fiore M, Aloe L. Exposure in fetus of methylazoxymethanol in the rat alters brain neurotrophins' levels and brain cells' proliferation. Neurotoxicol Teratol 2007;29:273-81.
52. Linden AM, Vaisanen J, Lakso M, Nawa H, Wong G, Castren E. Expression of neurotrophins BDNF and NT-3, and their receptors in rat brain after administration of antipsychotic and psychotrophic agents. J Mol Neurosci 2000;14:27-37.
53. Angelucci F, Mathe AA, Aloe L. Brain-derived neurotrophic factor and tyrosine kinase receptor TrkB in rat brain are significantly altered following haloperidone and risperidone administration. J Neurosci Res 2000;60:783-94.
54. Parikh V, Evans DR, Khan MM, Mahadik SP. Nerve growth factor in never-medicated first-episode psychotic and medicated chronic schizophrenic patients: possible implications for treatment outcome. Schiz Res 2003;60:117-23.
55. Takahashi M, Shirakawa O, Toyooka K, Kitamura N, Hashimoto T, Maeda K, Koizumi S, Wakabayashi K, Takahashi H, Someya T, Nawa H. Abnormal expression of brain-derived neurotrophic factor and its receptor in the corticolimbic system of schizophrenic patients. Mol Psych 2000;5:293-300.
56. Tan YL, Zhou DF, Cao LY, Zou YZ, Zhang XY. Decreased BDNF in serum of patients with chronic schizophrenia on long-term treatment with antipsychotics. Neurosci Lett 2005;382:27-32.
57. Lu XH, Dwyer DS. Second-generation antipsychotic drugs, olanzapine, quetiapine, and clozapine enhance neurite outgrowth in PC12 cells via PI3K/AKT, ERK, and pertussis toxin-sensitive pathways. J Mol Neurosci 2005;27:43-64.
58. Angelucci F, Aloe L, Iannitelli A, Gruber SH, Mathe AA. Effect of chronic olanzapine treatment on nerve growth factor and brain-derived neurotrophic factor in the rat brain. Eur Neuropsychopharmacol 2005;15:311-7.
59. Levi-Montalcini R. The nerve growth factor 35 years later. Science 1987;237:1154-62.
60. Pillai A, Terry A Jr, Mahadik SP. Differential effects of long-term treatment with typical and atypical antipsychotics on NGF and BDNF levels in rat striatum and hippocampus. Schiz Res 2006;82:95-106.
61. Terry AV, Jr Parikh V, Gearhart DA, Pillai A, Hohnadel E, Warner S, Nasrallah HA, Mahadik SP. Time-dependent effects of haloperidol and ziprasidone on nerve growth factor, cholinergic neurons, and spatial learning in rats. J Pharmacol Exp Ther 2006;318:709-24.
62. Millan MJ. Multi-target strategies for the improved treatment of depressive states. Conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther 2006;110:135-370.
63. Hennigan A, O'callaghan RM, Kelly AM. Neurotrophins and their receptors: roles in plasticity, neurodegeneration and neuroprotection. Biochem Soc Trans 2007;35(Pt 2):424-7.
64. Fiore M, Aloe L, Westenbroek C, Amendola T, Antonelli A, Korf J. Bromodeoxyuridine and methylazoxymethanol exposure during brain development affects behavior in rats: consideration for a role of nerve growth factor and brain derived neurotrophic factor. Neurosci Lett 2001;309:113-6.